Mesoblast hit with second shareholder class action over COVID-19 drug

Class Actions 2022-06-07 3:17 pm By Cat Fredenburgh | Melbourne

Please login to bookmark

Regenerative medicine company Mesoblast has been hit with a second class action for allegedly misleading shareholders about it Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au